FES Cycling With BFR in the Spinal Cord Injury Population
Recruiting
Phase 1
Interventional Study
Spinal Cord Injury
Cardio Vascular Disease
Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 6 (estimated)
- Sponsor
- Dr. B. Catharine. Craven · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury/disease (SCI/D) population. Many SCI/D patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk. CMD contributes to 46% of deaths, with 30-50% of the SCI/D population living with undiagnosed CMD. Treating CMD risk is more cha…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult (≥ 18 to ≤ 75yrs)
* Male or female
* Chronic Injury (\>1yr)
* Diagnosis of SCI at levels between C5 to T10 (AIS A-D) with traumatic or non-traumatic etiology.
* ≥3 Cardiometabolic risk parameters
Exclusion Criteria:
* A prior or current history of venous thromboembolis…
Contacts